RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mirati Therapeutics Stock

Mirati Therapeutics Net Income 2024

Mirati Therapeutics Net Income

-652.86 M USD

Ticker

MRTX

ISIN

US60468T1051

WKN

A1W1XV

In 2024, Mirati Therapeutics's profit amounted to -652.86 M USD, a -17.83% increase from the -794.51 M USD profit recorded in the previous year.

The Mirati Therapeutics Net Income history

YEARNET INCOME (undefined USD)
2030e1.22
2029e0.41
2028e0.14
2027e-0.15
2026e-0.41
2025e-0.54
2024e-0.65
2023e-0.79
2022-0.74
2021-0.58
2020-0.36
2019-0.21
2018-0.1
2017-0.07
2016-0.08
2015-0.06
2014-0.04
2013-0.05
2012-0.02
2011-0.01
2010-0.01
2009-0.02
2008-0.01
2007-0.02
2006-0.01
2005-0.01
2004-0.01
2003-0

Mirati Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Mirati Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Mirati Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Mirati Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Mirati Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Mirati Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Mirati Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Mirati Therapeutics’s growth potential.

Mirati Therapeutics Revenue, EBIT and net profit per share

DateMirati Therapeutics RevenueMirati Therapeutics EBITMirati Therapeutics Net Income
2030e2.79 B undefined1.32 B undefined1.22 B undefined
2029e1.44 B undefined387.13 M undefined414.29 M undefined
2028e1.03 B undefined87.82 M undefined140.78 M undefined
2027e736.43 M undefined-194.2 M undefined-146.81 M undefined
2026e505.03 M undefined-420.6 M undefined-413.76 M undefined
2025e329.19 M undefined-729.49 M undefined-544.87 M undefined
2024e182.56 M undefined-550.04 M undefined-652.86 M undefined
2023e62.95 M undefined-536.5 M undefined-794.51 M undefined
202212.44 M undefined-759.59 M undefined-740.87 M undefined
202172.09 M undefined-573.18 M undefined-581.78 M undefined
202013.4 M undefined-369.36 M undefined-357.94 M undefined
20193.34 M undefined-222.1 M undefined-213.26 M undefined
201812.93 M undefined-102.63 M undefined-98.42 M undefined
20170 undefined-71.54 M undefined-70.43 M undefined
20160 undefined-83.78 M undefined-83.12 M undefined
20150 undefined-64.71 M undefined-64.54 M undefined
20140 undefined-38.77 M undefined-43.7 M undefined
20130 undefined-30.97 M undefined-52.91 M undefined
20120 undefined-20.5 M undefined-20.29 M undefined
20113.13 M undefined-10.18 M undefined-9.84 M undefined
20102.32 M undefined-14.2 M undefined-14.22 M undefined
20092.65 M undefined-20.23 M undefined-20.68 M undefined
200827.64 M undefined-11.73 M undefined-8.36 M undefined
200714.44 M undefined-20.72 M undefined-20.52 M undefined
200614.13 M undefined-3.26 M undefined-6.62 M undefined
20055.52 M undefined-12.82 M undefined-12.63 M undefined
20046.51 M undefined-8.46 M undefined-8.46 M undefined
20037.15 M undefined-2.94 M undefined-3.91 M undefined

Mirati Therapeutics stock margins

The Mirati Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Mirati Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Mirati Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Mirati Therapeutics's sales revenue. A higher gross margin percentage indicates that the Mirati Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Mirati Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Mirati Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Mirati Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Mirati Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Mirati Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Mirati Therapeutics Margin History

Mirati Therapeutics Gross marginMirati Therapeutics Profit marginMirati Therapeutics EBIT marginMirati Therapeutics Profit margin
2030e95.18 %47.21 %43.67 %
2029e95.18 %26.98 %28.87 %
2028e95.18 %8.56 %13.72 %
2027e95.18 %-26.37 %-19.93 %
2026e95.18 %-83.28 %-81.93 %
2025e95.18 %-221.6 %-165.52 %
2024e95.18 %-301.29 %-357.61 %
2023e95.18 %-852.25 %-1,262.11 %
202295.18 %-6,106.03 %-5,955.55 %
202195.18 %-795.09 %-807.02 %
202095.18 %-2,756.42 %-2,671.19 %
201995.18 %-6,649.7 %-6,385.03 %
201895.18 %-793.74 %-761.18 %
201795.18 %0 %0 %
201695.18 %0 %0 %
201595.18 %0 %0 %
201495.18 %0 %0 %
201395.18 %0 %0 %
201295.18 %0 %0 %
2011128.43 %-325.24 %-314.38 %
2010137.93 %-612.07 %-612.93 %
200995.18 %-763.4 %-780.38 %
200895.18 %-42.44 %-30.25 %
200795.18 %-143.49 %-142.11 %
200695.18 %-23.07 %-46.85 %
200595.18 %-232.25 %-228.8 %
200495.18 %-129.95 %-129.95 %
200395.18 %-41.12 %-54.69 %

Mirati Therapeutics Aktienanalyse

What does Mirati Therapeutics do?

Mirati Therapeutics Inc is a biotechnology company based in San Diego, California, that focuses on the discovery and development of personalized therapies for cancer. The company was founded in 1995 and originally focused on developing drugs for the treatment of inflammatory diseases. However, in 2012, the company changed its strategy and began to focus on cancer therapies. Mirati Therapeutics' business model is based on the discovery and development of drugs for cancer patients with specific genetic mutations or abnormalities. The company utilizes new insights in cancer genomics to develop targeted therapeutic approaches tailored to the specific needs of cancer patients. The company operates in three different business areas: preclinical research, clinical development, and commercial products. In the preclinical research area, the company focuses on investigating new target candidates and identifying potential drugs for the treatment of cancer. Clinical development involves conducting clinical trials to evaluate the effectiveness and safety of drugs in relation to specific types of cancer. The company also works on marketing and selling commercial products that are already approved on the market and used for the treatment of cancer. One of Mirati Therapeutics' products is the drug Adagrasib, a treatment for patients with advanced non-small cell lung cancer (NSCLC) and specific genetic mutations. Adagrasib aims to inhibit the activity of KRAS, an oncogene that is overexpressed in many types of cancer. The company also has other drugs in the pipeline that are still in preclinical or clinical development. Mirati Therapeutics has partnerships with other companies in the biotech and pharmaceutical industries to advance the discovery and development of new therapies. In 2020, the company announced a strategic collaboration with the pharmaceutical company Amgen to combine Amgen's KRAS inhibitor portfolio with Mirati's and receive milestone payments. The company works closely with the FDA and other regulatory authorities to obtain approval for new drugs and demonstrate the safety and efficacy of its products. The company has made significant progress in the development of personalized cancer therapies in recent years and hopes to be able to help even more patients in the future. In summary, Mirati Therapeutics Inc is an innovative biotechnology company that focuses on the discovery and development of personalized cancer therapies. The company collaborates closely with other industry partners to develop and bring new drugs to the market. Mirati Therapeutics strives to improve the lives of cancer patients and hopes to offer even more innovative therapies in the future. Mirati Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Mirati Therapeutics's Profit Margins

The profit margins of Mirati Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Mirati Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Mirati Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Mirati Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Mirati Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Mirati Therapeutics stock

How much profit has Mirati Therapeutics made this year?

Mirati Therapeutics has made -652.86 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -17.83% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Mirati Therapeutics publish its earnings?

Mirati Therapeutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Mirati Therapeutics?

The profits of Mirati Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Mirati Therapeutics?

You can learn more about the earnings of Mirati Therapeutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Mirati Therapeutics pay?

Over the past 12 months, Mirati Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mirati Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Mirati Therapeutics?

The current dividend yield of Mirati Therapeutics is .

When does Mirati Therapeutics pay dividends?

Mirati Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mirati Therapeutics?

Mirati Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Mirati Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mirati Therapeutics located?

Mirati Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mirati Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mirati Therapeutics from 12/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/19/2024.

When did Mirati Therapeutics pay the last dividend?

The last dividend was paid out on 12/19/2024.

What was the dividend of Mirati Therapeutics in the year 2023?

In the year 2023, Mirati Therapeutics distributed 0 USD as dividends.

In which currency does Mirati Therapeutics pay out the dividend?

The dividends of Mirati Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Mirati Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Mirati Therapeutics

Our stock analysis for Mirati Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mirati Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.